{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:25:09Z","timestamp":1790601909020,"version":"4.1.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Malaria case management in Ghana is a key intervention within the national malaria elimination agenda. Currently, artesunate-amodiaquine (AS-AQ), artemetherlumefantrine (AL), and artesunate-pyronaridine (AP) are the first-line medicines for treating uncomplicated malaria whilst dihydroartemisinin-piperaquine (DHAP) is the second-line medicine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This was a one-arm prospective evaluation of the clinical, parasitological and haematological responses of children (6 months to 9 years old) treated with DHAP in five (5) sentinel sites and AP in four (4) sentinel sites between August and December, 2023 using the WHO protocol on surveillance of antimalarial drug efficacy. The DHAP study was a follow-up to the baseline conducted in 2020\/2021, and the AP study was to provide baseline data after its introduction in 2022. The 3\/3 PCR-genotyping approach distinguished between reinfection and recrudescence using merozoite surface protein 1 (\n                      <jats:italic>msp1<\/jats:italic>\n                      )-specific primers: RO33, MAD20, K1; merozoite protein 2 (\n                      <jats:italic>msp2<\/jats:italic>\n                      )-specific primers: IC 3D7 and FC; and glutamate-rich protein (\n                      <jats:italic>glurp<\/jats:italic>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PCR-uncorrected cure rates on day-42 ranged between 98.8% (95% CI: 93.2-100) and 100% for DHAP with an overall PCR-uncorrected cure rate of 99.2% (95% CI: 97.6-99.8); and between 85.0% (95% CI: 70.2-94.3) and 100% for AP with an overall PCR-uncorrected cure rate of 96.2% (95% CI: 92.9-98.0). PCR-corrected cure rates on day-42 was 100% in all DHAP sites; and ranged between 91.9% (95% CI: 78.1-98.3) and 100% for AP with an overall PCR-corrected cure rate of 97.3% (95% CI: 94.3-98.8). Day-3 parasitemia was prevalent in only one (1) DHAP site (1\/60 \u2013 1.7%) and one (1) AP site (1\/65 \u2013 1.5%) with an overall prevalence of 0.3% for DHAP and 0.4% for AP. Neither treatment with DHAP nor AP resulted in an early treatment failure (ETF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We conclude that the therapeutic efficacy level of DHAP has remained high (&amp;gt;90%) since the baseline study in 2020\/2021. Also, the baseline efficacy level of AP is high (&amp;gt;90%) warranting the use of both DHAP and AP in the treatment of uncomplicated malaria in the country.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2025.1715777","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T06:36:49Z","timestamp":1767595009000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic efficacy of dihydroartemisinin-piperaquine and artesunate-pyronaridine combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Ghana, 2023"],"prefix":"10.3389","volume":"13","author":[{"given":"Benjamin","family":"Abuaku","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana","place":["Accra, Ghana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Boateng","sequence":"additional","affiliation":[{"name":"National Malaria Elimination Program, Public Health Division, Ghana Health Service","place":["Accra, Ghana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana Yaw","family":"Peprah","sequence":"additional","affiliation":[{"name":"National Malaria Elimination Program, Public Health Division, Ghana Health Service","place":["Accra, Ghana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Asamoah","sequence":"additional","affiliation":[{"name":"National Malaria Elimination Program, Public Health Division, Ghana Health Service","place":["Accra, Ghana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy Odurowah","family":"Duah-Quashie","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana","place":["Accra, Ghana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sena Adzoa","family":"Matrevi","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana","place":["Accra, Ghana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice Obeng","family":"Amoako","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana","place":["Accra, Ghana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neils","family":"Quashie","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana","place":["Accra, Ghana"]},{"name":"Centre for Tropical Clinical Pharmacology and Therapeutics, University of Ghana Medical School","place":["Accra, Ghana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Owusu-Antwi","sequence":"additional","affiliation":[{"name":"World Health Organization, Country Office","place":["Accra, Ghana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwadwo Ansah","family":"Koram","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana","place":["Accra, Ghana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keziah Laurencia","family":"Malm","sequence":"additional","affiliation":[{"name":"National Malaria Elimination Program, Public Health Division, Ghana Health Service","place":["Accra, Ghana"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"ref1","volume-title":"World Malaria Report 2024: addressing inequity in the global malaria response","year":"2024"},{"key":"ref2","volume-title":"National Malaria Elimination Strategic Plan (NMESP) of Ghana: 2024\u20132028","year":"2023"},{"key":"ref3","volume-title":"WHO guidelines for malaria, 30 November 2024","year":"2024"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1186\/s12879-021-06961-4","article-title":"Trends and predictive factors for treatment failure following artemisinin-based combination therapy among children with uncomplicated malaria in Ghana: 2005-2018","volume":"21","author":"Abuaku","year":"2021","journal-title":"BMC Infect Dis"},{"key":"ref5","volume-title":"Guidelines for case management of malaria in Ghana","year":"2009"},{"key":"ref6","volume-title":"Guidelines for case management of malaria in Ghana. Accra: Ministry of Health","year":"2020"},{"key":"ref7","volume-title":"Antimalarial Medicine Policy, Ghana","year":"2022"},{"key":"ref8","volume-title":"Malaria case management manual: National Malaria Elimination Program (NMEP), 2023","year":"2023"},{"key":"ref9","volume-title":"Methods for surveillance of antimalarial drug efficacy","year":"2009"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1058660","DOI":"10.3389\/fcimb.2022.1058660","article-title":"Therapeutic efficacy of dihydroartemisinin-piperaquine combination for the treatment of uncomplicated malaria in Ghana","volume":"12","author":"Abuaku","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12936-019-2848-1","article-title":"Therapeutic efficacy of artesunate-amodiaquine and artemether-lumefantrine combinations for uncomplicated malaria in 10 sentinel sites across Ghana: 2015\u20132017","volume":"18","author":"Abuaku","year":"2019","journal-title":"Malar J"},{"key":"ref12","first-page":"29","article-title":"Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations","volume-title":"Informal consultation organized by the Medicines for Malaria Venture and cosponsored by the World Health Organization","year":"2008"},{"key":"ref13","volume-title":"Informal consultation on methodology to distinguish reinfection from recrudescence in high malaria transmission areas: Report of a virtual meeting, 17\u201318 may 2021","year":"2021"},{"key":"ref14","volume-title":"Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010\u20132019)","year":"2020"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12936-023-04574-7","article-title":"Efficacy and safety of pyronaridine-artesunate versus artemether-lumefantrine in the treatment of acute uncomplicated malaria in children in south-West Nigeria: an open-labelled randomized controlled trial","volume":"22","author":"Falade","year":"2023","journal-title":"Malar J"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12936-024-04922-1","article-title":"Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine and prevalence of molecular markers of anti-malarial drug resistance in children in Togo, 2021","volume":"23","author":"Dorkenoo","year":"2024","journal-title":"Malar J"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12936-023-04618-y","article-title":"Therapeutic efficacy of pyronaridine-artesunate (Pyramax\u00ae) against uncomplicated plasmodium falciparum infection at Hamusit health Centre, Northwest Ethiopia","volume":"22","author":"Alebachew","year":"2023","journal-title":"Malar J"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"106658","DOI":"10.1016\/j.ijantimicag.2022.106658","article-title":"Artemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated plasmodium falciparum malaria in Grande Comore Island: an open-label, non-randomized controlled trial","volume":"60","author":"Li","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12936-021-03845-5","article-title":"Is there evidence of anti-malarial multidrug resistance in Burkina Faso?","volume":"20","author":"Rasmussen","year":"2021","journal-title":"Malar J"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12936-025-05473-9","article-title":"Efficacy of artemether-lumefantrine, artesunate-amodiaquine, dihydroartemisinin-piperaquine and artesunate-pyronaridine for the treatment of uncomplicated plasmodium falciparum malaria in Mozambique, 2022","volume":"24","author":"Nhama","year":"2025","journal-title":"Malar J"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00407-4","article-title":"Efficacies of artemether-lumefantrine, artesunate-amodiaquine, dihydroartemisinin-piperaquine, and artesunate-pyronaridine for the treatment of uncomplicated plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomized, open-label, phase 4 clinical trial","volume":"19","author":"Kamya","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12936-021-03711-4","article-title":"Efficacy and safety of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated plasmodium falciparum malaria in Ugandan children: a systematic review and meta-analysis of randomized control trials","volume":"20","author":"Asefa","year":"2021","journal-title":"Malar J"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e0264339","DOI":"10.1371\/journal.pone.0264339","article-title":"Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated plasmodium falciparum malaria in sub-Saharan Africa: a systematic review and meta-analysis","volume":"17","author":"Marwa","year":"2022","journal-title":"PLoS One"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.23937\/2474-3658\/1510242","article-title":"Efficacy and safety assessment of three artemisinin-based combination therapy (ACTs) in the treatment of P. Falciparum malaria in Cameroon","volume":"7","author":"Metoh","year":"2021","journal-title":"J Infect Dis Epidemiol"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1715777\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T13:21:35Z","timestamp":1769001695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1715777\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":24,"alternative-id":["10.3389\/fpubh.2025.1715777"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1715777","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"article-number":"1715777"}}